Topical pharmaceutical composition of adapalene and minocycline

A pharmaceutical composition for topical application comprising:

• a. from about 0.1% w/w to about 0.3% w/w adapalene or a pharmaceutically acceptable salt thereof;
• b. about 1.0% w/w to about 10% w/w minocycline or a pharmaceutically acceptable salt thereof;
• c. a gelling agent;
• d. a silicone oil;
• e. a non-aqueous solvent;
• and
• f. optionally, one or more pharmaceutically acceptable excipient thereof;
• wherein the composition is a non-aqueous pharmaceutical composition.

A pharmaceutical composition for topical application comprising:

• a. from about 0.1% w/w to about 0.3% w/w adapalene or a pharmaceutically acceptable salt thereof;
• b. from about 1.0% w/w to about 10% w/w minocycline or a pharmaceutically acceptable salt thereof;
• c. from about 40% w/w to about 70% w/w of a gelling agent selected from cyclopentasiloxane and dimethicone cross polymer;
• d. a silicone oil selected from dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer;
• e. from about 10% w/w to about 99% w/w a non-aqueous solvent selected from mineral oil, light mineral oil, triglycerides, medium chain triglyceride, capric/caprylic triglyceride isopropyl palmitate, isopropyl myristate, isopropyl isostearate, poly propylene glycol 15-stearly ether, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, and maleated soybean oil;
• and
• f. optionally, one or more pharmaceutically acceptable excipient thereof.

A method for treating acne in a subject in need thereof comprising topically administering a pharmaceutical composition comprising:

• a. about 0.01% w/w to about 1.0% w/w adapalene or a pharmaceutically acceptable salt thereof;
• b. about 0.01% w/w to about 20% w/w minocycline or a pharmaceutically acceptable salt thereof;
• c. about 10% w/w to about 99% w/w by weight of non-aqueous solvent or mixtures;
• and
• d. about 0.05% w/w to about 75% w/w of gelling agent.

A pharmaceutical composition for topical application comprising:

• a. from about 1.0% w/w to about 10% w/w minocycline or a pharmaceutically acceptable salt thereof;
• b. from about 40% w/w to about 70% w/w of a gelling agent selected from cyclopentasiloxane and dimethicone cross polymer;
• c. a silicone oil selected from dimethicone, cyclomethicone, polyalkyl siloxane, polyaryl siloxane, polyalkylaryl siloxane, a polyether siloxane copolymer and a poly(dimethylsiloxane)-(diphenyl-siloxane) copolymer;
• and
• d. from about 10% w/w to about 99% w/w a non-aqueous solvent selected from mineral oil, light mineral oil, triglycerides, medium chain triglyceride, capric/caprylic triglyceride isopropyl palmitate, isopropyl myristate, isopropyl isostearate, poly propylene glycol 15-stearly ether, octyl palmitate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, and maleated soybean oil;
• and
• e. optionally, one or more pharmaceutically acceptable excipient thereof.